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Purpose: To assess the contribution of rare variants in the genetic
background toward variability of neurodevelopmental phenotypes
in individuals with rare copy-number variants (CNVs) and gene-
disruptive variants.
Methods: We analyzed quantitative clinical information, exome
sequencing, and microarray data from 757 probands and 233
parents and siblings who carry disease-associated variants.
Results: The number of rare likely deleterious variants in
functionally intolerant genes (“other hits”) correlated with expres-
sion of neurodevelopmental phenotypes in probands with 16p12.1
deletion (n=23, p=0.004) and in autism probands carrying gene-
disruptive variants (n=184, p=0.03) compared with their carrier
family members. Probands with 16p12.1 deletion and a strong
family history presented more severe clinical features (p=0.04) and
higher burden of other hits compared with those with mild/no
family history (p=0.001). The number of other hits also correlated
with severity of cognitive impairment in probands carrying
pathogenic CNVs (n=53) or de novo pathogenic variants in
disease genes (n=290), and negatively correlated with head size
among 80 probands with 16p11.2 deletion. These co-occurring hits
involved known disease-associated genes such as SETD5, AUTS2,
and NRXN1, and were enriched for cellular and developmental
processes.
Conclusion: Accurate genetic diagnosis of complex disorders will
require complete evaluation of the genetic background even after a
candidate disease-associated variant is identified.
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INTRODUCTION
Significant advances in high-throughput genomic sequencing
technologies have helped to identify hundreds of genes as risk
factors for neurodevelopmental and neuropsychiatric dis-
orders, including autism, intellectual disability, schizophrenia,
and epilepsy. For example, in 2002, only 2–3% of autism cases
were explained by genetic factors, whereas current studies
suggest that rare disruptive variants, including copy-number
variants (CNVs) and single-nucleotide variants (SNVs),
account for 10–30% of autism cases.1 Despite initial claims
of association with a specific disorder or syndrome, several of
these pathogenic variants show incomplete penetrance and
variable expressivity.2–4 For example, the 16p11.2 BP4-BP5
deletion (OMIM 611913) was first described in children with
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autism, but further studies on other clinical and population
cohorts demonstrated that this deletion is also associated with
intellectual disability and developmental delay (ID/DD),
obesity, epilepsy, cardiac disease, and scoliosis, and only
about 24% of cases manifest an autism phenotype.5–7
Phenotypic variability is not restricted to multigenic CNVs
but has also been reported for single genes with pathogenic
variants, including DISC1, PTEN, SCN1A, CHD2, NRXN1,
FOXP2, and GRIN2B.3 While some of these effects could be
due to allelic heterogeneity, phenotypic variability among
carriers of the same molecular lesion suggests a strong role for
variants in the genetic background.8,9 For example, in a large
family described by St. Clair and colleagues,10 carriers of a
balanced translocation disrupting DISC1 manifested a wide
range of neuropsychiatric features, including schizophrenia,
bipolar disorder, and depression. This phenomenon was
exemplified by our delineation of a 520-kbp deletion on
chromosome 16p12.1 (OMIM 136570), which is associated
with developmental delay and extensive phenotypic varia-
bility.11 Interestingly, in most cases, this deletion was
inherited from a parent who also manifested mild neuropsy-
chiatric features, and the severely affected children were more
likely to carry another large (>500 kbp) rare CNV. We
hypothesized that while each pathogenic primary variant
sensitizes the genome to varying extents, additional rare
variants in the genetic background modulate the ultimate
clinical manifestation.
Recent studies have identified secondary disease-associated
variants that explain atypical clinical presentations of
individuals carrying a primary variant.12–14 While these
studies have explained phenotypic variability on a case-by-
case basis, the global effect of the genetic background toward
phenotypic variability among individuals sharing the same
pathogenic variant has not been assessed. In this study, we
evaluated 757 probands and 233 family members carrying
primary variants associated with neurodevelopmental disease
(17 rare CNVs or pathogenic variants in 301 genes). A
comparison of the genetic background between probands and
parents or siblings showed that in the presence of the same
primary variant, variability and severity of neurodevelop-
mental disease correlates with the number of other rare
variants, suggesting a global role of the genetic background
toward phenotypic heterogeneity.
MATERIALS AND METHODS
Cohorts analyzed
We analyzed clinical and genetic data in five subgroups of
individuals carrying a disease-associated primary variant
(Fig. 1): (1) 26 probands, 23 carrier parents and available
family members carrying 16p12.1 deletion; (2) 53 autism
probands from the Simons Simplex Collection (SSC) cohort
who carry rare CNVs associated with syndromic and variably
expressive genomic disorders;2 (3) 84 probands and available
family members with 16p11.2 BP4-BP5 deletion from the
Simons Variation in Individuals Project (SVIP) cohort; (4)
295 autism probands from the SSC cohort reported to carry
severe de novo loss-of-function variants in neurodevelop-
mental genes;15,16 and (5) 184 probands and matched
unaffected siblings from the SSC cohort who inherited the
same rare (≤0.1% frequency) loss-of-function or likely
damaging missense primary variants (CADD ≥25) in genes
recurrently disrupted in neurodevelopmental disorders.17
Patient recruitment and clinical data ascertainment
We obtained clinical and/or genomic data from 141 children
carrying the 16p12.1 deletion, as well as 39 deletion carrier
and 30 noncarrier parents. Probands and parents recruited
through direct contact provided consent according to the
protocol reviewed and approved by The Pennsylvania State
University Institutional Review Board (IRB). When indivi-
duals were not contacted directly, de-identified phenotypic
and genomic data were used; as such, these cases were exempt
from IRB review and conformed to the Helsinki Declaration.
We extracted clinical information from medical records or
clinical questionnaires completed by different physicians from
180 carrier individuals and available family members
(Supplementary Method 1.1). We used a modified de Vries
scoring system for quantifying the number and severity of
phenotypic abnormalities in affected children, which allows
for a uniform assessment of developmental phenotypes from
clinical records (Table S1).18 Family history information was
used to bin families with the deletion into strong and mild or
negative family history categories based on the severity of
neurodevelopmental or psychiatric features (Fig. S1, Supple-
mentary Method 1.1). Genomic and clinical data for SSC and
SVIP cohort families were obtained from the Simons
Foundation Autism Research Initiative (SFARI) following
appropriate approvals (see Supplementary Method 1.1).
Burden analysis of rare variants in the genetic background
(“other hits”)
To identify all coding variants modulating the presentation of
the 16p12.1 deletion, we performed exome sequencing and
single-nucleotide polymorphism (SNP) arrays on 105 indivi-
duals from 26 families as previously reported (Supplementary
Method 1.2). Variant calls (SNVs and CNVs) from 716
individuals in the SSC were obtained from exome and SNP
microarray studies,15,16,19 and variant call files (VCF) and
SNP array data from 84 families with 16p11.2 BP4-BP5
deletion were obtained from the Simons Foundation. We
defined “rare variants” or “other hits” as additional rare likely
deleterious variants (includes ≤0.1% frequency CNV or SNV
with CADD ≥25) (ref. 20) affecting a functionally intolerant
gene (RVIS ≤20th percentile) co-occurring in an individual
who already carries a disease-associated primary variant
(Fig. 1a, Supplementary Method 1.2). The Residual Variation
Intolerance Score (RVIS) has been shown to be a good
predictor of gene intolerance to deleterious variants and has
been widely used by multiple studies for the recapitulation of
known and the discovery of novel disease-associated
genes.16,21 The biological function of genes with other hits
was analyzed using Ingenuity Pathway Analysis (IPA, Qiagen
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Bioinformatics), expression data derived from the GTEx
consortium,22 and Gene Ontology (GO) enrichment analy-
sis23 (Supplementary Method 1.3).
RESULTS
Rare variants in the genetic background and disease
expressivity in 16p12.1 deletion probands
We assessed how rare likely deleterious variants in the genetic
background can modulate phenotypes in concert with a
primary variant by evaluating 757 affected probands and 233
family members carrying disease-associated variants (rare
CNVs or pathogenic SNVs) (Fig. 1, see Methods). Using the
16p12.1 deletion as a paradigm for studying the genetic basis
of variable expression of disease traits, we analyzed 180
individuals with the deletion and their noncarrier family
members (Fig. 1b). The 16p12.1 deletion was inherited in
92.4% of cases, with a significant maternal bias (57.6%
maternal [n=53] vs. 34.8% paternal [n=32], one-tailed
binomial test p=0.01) (Table S2). In accordance with the
female protective model described for neurodevelopmental
disorders,2,24,25 we observed a significant gender bias among
probands with the 16p12.1 deletion (67.9% males vs. 32.1%
females, one-tailed binomial test p<0.0001). Detailed clinical
analysis of 141 affected children with 16p12.1 deletion showed
a wide heterogeneity of phenotypes, with a high prevalence of
neurodevelopmental, craniofacial, and musculoskeletal fea-
tures (>50%), and variable involvement of other organs and
systems (Fig. 2a, Table S3). In contrast, 32 of 39 (82%) (61.5%
females, 38.5% males) carrier parents showed mild cognitive,
behavioral, and/or psychiatric features (Table S4), consistent
with previous reports of cognitive impairment and increased
risk for schizophrenia in carriers of the 16p12.1 deletion.26,27
To identify variants within protein-coding regions that
contribute to a more severe manifestation of the deletion in
the affected children compared with their carrier parents, we
performed exome sequencing and high-resolution SNP arrays
in 26 families (n=105) with 16p12.1 deletion (23 inherited
and 3 de novo cases, Table S5). We first evaluated whether the
deletion could unmask recessive alleles, and found no rare
pathogenic variants within the seven 16p12.1 genes on the
nondeleted chromosome (Table S6). We next performed a
case-by-case analysis of families for other hits elsewhere in the
genome by focusing on rare CNVs (≤0.1%, ≥50 kbp), de novo
or rare (ExAC frequency ≤0.1%) loss-of-function (LoF)
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Fig. 1 Strategy for understanding the role of the genetic background in phenotypic variability of neurodevelopmental disease. (a) Schematic
of primary variants and other hits used in this study. Disease-associated variants shared among different individuals were considered as “primary variants”
(blue box), and rare likely deleterious single-nucleotide variants (SNVs) or copy-number variants (CNVs) affecting functionally intolerant genes were defined
as “other hits” (blue Xs). Individuals with a higher burden of other hits (in red) exhibit a more severe clinical manifestation compared with those carrying the
same primary variant but with a lower number of other hits (in gray). (b) Combined clinical and genomic analysis of 757 probands and 233 family members
carrying primary disease-associated variants (16p12.1 deletion, 16p11.2 deletion, 16 rare CNVs, de novo pathogenic variants in autism simplex cases, and
inherited pathogenic variants in disease-associated genes) was performed to understand the role of rare (≤0.1%) likely deleterious variants (SNVs with CADD
≥25 and CNVs) in functionally intolerant genes (Residual Variation Intolerance Score [RVIS] ≤20th percentile) toward the variable manifestation of neu-
rodevelopmental disease. SRS Social Responsiveness Scale
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variants, and rare likely damaging missense variants (Phred-
like CADD ≥25) in disease-associated genes (see Methods,
Tables S7–S9). For example, we identified two disease-
associated variants in proband P1C_01, including a de
novo LoF variant in the intellectual disability–associated
gene SETD5 (OMIM 615761, c.1623_1624insAC, p.
Asp542Thrfs*3) and a LoF variant in DMD (OMIM 310200,
c.9G>A, p.Trp3X) transmitted from the non-16p12.1-deletion
carrier mother (Fig. 2b). Similarly, a rare deletion at 2p16.3
encompassing NRXN1 (OMIM 614332), inherited from the
noncarrier mother, was identified in proband PC_11 (Fig. 2b).
While private disease-associated variants may explain the
variable and severe features in the affected children on a case-
by-case basis, we lacked the statistical power to implicate
individual genes or variants that modulate specific 16p12.1
deletion phenotypes. Therefore, to globally assess the genome-
wide contribution of rare likely deleterious variants affecting
functionally relevant genes, we performed an integrative
analysis and quantified rare (frequency ≤0.1%), likely
deleterious variants (CNVs or SNVs with CADD ≥25) within
genes intolerant to functional variation (RVIS ≤20th percen-
tile),16,20,21 hereafter referred to as the “burden of other hits.”
Intrafamilial comparison showed that probands have an
excess of other hits compared with their carrier parents
(Wilcoxon signed-rank test, p=0.004, Fig. 2c and S2), with no
change in the number of synonymous variants in all genes
(p=0.29) or in RVIS ≤20th genes (p=0.36, Fig. S2E, F).
Further, functional analysis of genes with other hits showed
that probands presented an excess of genes that were
preferentially expressed in the human brain (Wilcoxon
signed-rank test, p=0.04, Fig. S3) and enriched for develop-
mental pathways (Table S10) compared with carrier parents.
The severity and variability of neurodevelopmental features
is contingent upon family history of neuropsychiatric
disease.25 In fact, the cognitive and social outcomes in
probands with de novo 16p11.2 BP4-BP5 deletion or 22q11.2
deletions have been reported to positively correlate with the
cognitive and social skills of their parents.28,29 However, the
genetic basis of such background effects has not been
specifically studied. We assessed the role of other hits toward
family-specific background effects and in the observed
interfamilial variability of clinical features in probands with
16p12.1 deletion. We found that probands with a strong
family history of neurodevelopmental and psychiatric disease
presented a more severe and heterogeneous clinical presenta-
tion (Mann–Whitney one-tailed, p=0.04) and a higher
burden of other hits (p=0.001) than those with mild or
negative family history (Figs. 3a–c and S4A–C). Interestingly,
probands with a strong family history also showed a higher
difference in burden compared with their carrier parents than
probands with a mild family history (p=0.003, Fig. 3d). While
we did not observe a difference in burden between carrier
parents based on family history (p=0.68, Fig. S4B), we found
that noncarrier parents with a strong family history presented
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Fig. 2 Rare variants in the genetic background contribute to the phenotypic heterogeneity in 16p12.1 deletion. (a) Phenotypic spectrum of
16p12.1 deletion in probands (n=141, red) and carrier parents (n=39, gray). Probands exhibit a spectrum of severe developmental features compared with
the mild cognitive and psychiatric features observed in carrier parents. Features represented were observed in ≥5% of probands or carrier parents.
(b) Example of families with inherited 16p12.1 deletion. Family 1 (left) shows three generations carrying 16p12.1 deletion and multiple neurodevelopmental
and psychiatric features, with the proband (P1C_01, indicated with arrow) carrying a de novo loss-of-function variant in SETD5 (p.Asp542Thrfs*3) and a
stopgain variant in DMD gene (p.Trp3X) inherited from the mother without the 16p12.1 deletion (noncarrier). Family 2 (right) shows a proband (PC_11,
indicated with arrow) with multiple congenital and neurodevelopmental features carrying 16p12.1 deletion and 2p16.3 deletion (encompassing NRXN1),
the latter inherited from the noncarrier mother. (c) Analysis of rare (≤0.1%) likely deleterious variants (single-nucleotide variants with CADD ≥25) in genes
intolerant to functional variation (RVIS ≤20th percentile) in proband–carrier parent pairs shows that probands present a higher burden of other hits
compared with their carrier parents (n=23, Wilcoxon signed-rank test, p=0.004). ADHD attention deficit hyperactivity disorder
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a significantly higher burden compared with those with a mild
family history (p=0.01, Fig. 3e). Therefore, in families with a
strong history of neurodevelopmental and psychiatric disease,
a higher number of rare variants in the genetic background
are more likely to be transmitted to the proband from the
noncarrier parent, potentially contributing to a more severe
manifestation of the disorder. These results suggest a potential
role for rare variants in the genetic background in modulating
intra- and interfamilial clinical variability observed in families
with the 16p12.1 deletion.
Burden of other rare variants correlates with quantitative
phenotypes among individuals with 16p11.2 deletion and
other rare pathogenic CNVs
We next assessed whether the burden of other rare variants
modulates quantitative phenotypes in carriers of other CNVs
associated with neurodevelopmental phenotypes (Fig. 1b). In
autism probands with disease-associated rare CNVs (n= 53,
Table S11) from the Simons Simplex Cohort (SSC), we
observed a modest but significant negative correlation
(Pearson correlation, R= –0.36, p= 0.004) between the
number of other hits and full-scale IQ (FSIQ) scores (Fig. 4a).
This result held true when we separately analyzed individuals
carrying 16p11.2 BP4-BP5 deletion (R= –0.68, p= 0.04), but
did not show statistical significance for 16p11.2 BP4-BP5
duplication (R= –0.34, p= 0.17), 1q21.1 duplication (R
= –0.36, p= 0.32), or 7q11.23 duplication (R= –0.74, p=
0.17), potentially due to low sample sizes (Figs. 4a and S5).
Interestingly, probands with disease-associated CNVs and
intellectual disability (FSIQ <70) showed a significant increase
in the number of other hits compared with those without
intellectual disability (FSIQ ≥70, one-tailed Mann–Whitney,
p=0.02, Fig. S6).
We further expanded our analysis by evaluating a larger set
of 84 families with 16p11.2 BP4-BP5 deletion from the
Simons Variation in Individuals Project (SVIP). We observed
a higher median number of other hits in probands carrying
the 16p11.2 deletion that had intellectual disability (FSIQ <70,
median=8) compared with those with no intellectual
disability (FSIQ ≥70, median=7 one-tailed Mann–Whitney,
p= 0.08, Fig. 4b), without a difference in the number of
synonymous variants between the two subgroups (median of
9957 synonymous changes for FSIQ <70 group versus 10,052
for the FSIQ ≥70 group, two-tailed Mann–Whitney, p= 0.51,
Fig. S7A). Notably, we observed only a mild negative
correlation between the burden of other hits and FSIQ, which
did not attain statistical significance (Pearson correlation,
R= –0.16, p= 0.08, Fig. S7B). Even though the sample size in
the SSC cohort (n= 8) is small, we hypothesized that this
marginal significance compared with 16p11.2 deletion pro-
bands from the SSC cohort (Figs. 4a and S5B) could be due to
differences in clinical ascertainment. The SVIP cohort was
selected for individuals carrying a 16p11.2 deletion who
manifested a more heterogeneous set of phenotypes, while
individuals from the SSC cohort were specifically ascertained
for idiopathic autism.30 These differences in ascertainment
were evident by different distributions of quantitative
phenotypes, including body mass index (BMI), FSIQ, and
SRS T-scores, in both populations (Fig. S8).
After adjusting for age to allow for full manifestation of the
head phenotype, we identified a negative correlation between
the number of other hits in SVIP probands with 16p11.2
deletion and their head circumference (HC) z-scores (age
≥12 months, n= 80, Pearson’s R= –0.26, p= 0.009,
Fig. 4c).6,7 The observation that HC z-scores decline steadily
(from >2 to <–2 scores) as other hits accumulate confirms
that the deletion primarily leads to macrocephaly phenotypes,
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Fig. 3 Strong family history of neurodevelopmental and psychiatric
disease is associated with an excess of other hits and severe
phenotypic outcome in 16p12.1 deletion probands. (a) Diagram
showing phenotypic heterogeneity in 16 probands with 16p12.1 deletion
(black=phenotype present, white=absent, gray=not assessed) and their
family history of neurodevelopmental and psychiatric disease (red=strong,
blue=mild/negative). Probands with strong family history (n=9) have (b) a
more heterogeneous clinical manifestation (higher de Vries scores, one-
tailed Mann–Whitney, p=0.04) and (c) a higher burden of other hits (one-
tailed Mann–Whitney p=0.001) than those with mild or negative family
history (n=7). (d) Probands with a strong family history exhibit a greater
difference in burden of other hits compared with carrier parents (p=0.003).
(e) Noncarrier parents from families with strong family history present a
higher burden compared with those with mild/negative family history (one-
tailed Mann–Whitney, p=0.01). NC Noncarrier
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and suggests that rare variants in the genetic background
could explain the incomplete penetrance of this phenotype
among carriers of the deletion.7 We note that the burden of
other hits did not correlate with Social Responsiveness Scale
(SRS) T-scores or body mass index (BMI) z-scores, measures
for autism and obesity, among probands with rare CNVs from
the SSC cohort (Fig. S9A, B) or those with 16p11.2 deletion
from the SVIP cohort (Fig. S9C, D), suggesting other
mechanisms for the variability of these phenotypes.
Rare variants in the genetic background modulate disease
manifestation among individuals with disruptive variants
in disease-associated genes
We next analyzed 295 autism simplex cases from the SSC
cohort with previously identified de novo gene-disruptive
variants within 271 genes,15,16 and observed a moderately
negative correlation between the burden of other hits and
FSIQ scores (Spearman’s correlation, R= –0.25, p < 0.0001,
Fig. 4d). Within this cohort, individuals with intellectual
disability (FSIQ <70, n= 93) presented an enrichment of
other hits compared with those without intellectual disability
(FSIQ ≥70, n= 197) (one-tailed Mann–Whitney, p= 0.001,
Fig. S10A). We did not observe a role for the burden of other
hits in modulating BMI z-scores (Spearman’s R= –0.038, p=
0.27, Fig. S10B), although we did find a mild but significant
positive correlation with SRS T-scores (Spearman’s R= 0.12,
p= 0.02, Fig. S10C). Moreover, when probands were
separated by gender, we observed a higher burden of other
hits in females compared with males (one-tailed
Mann–Whitney, p=0.02, Fig. S11). This supports the
hypothesis that females require a higher contribution from
the genetic background to reach the genetic threshold for
pathogenesis of neurodevelopmental disease than males.25
While there is a consensus on the pathogenic role of de
novo gene-disruptive variants in simplex families, the
interpretation of inherited pathogenic variants within the
FS
IQ
 
H
C 
z-
sc
or
e
0.0
–4.0
4.0
0
100
50
150
1q21.1 dup
7q11.23 dup
Other CNVs
Linear fits
n = 53
R = –0.36
p = 0.004
16p11.2 dup
16p11.2 del
2.0
–2.0
6.0
0 5 10 15 20 25
Number of other hits
FS
IQ
0
100
50
150
FS
IQ
<70
≥70
b
n = 82
p = 0.08
16p11.2 del
n = 80
R = –0.26
p = 0.009
16p11.2 delMacrocephaly
Microcephaly
Proband
Sibling
FS
IQ
<70
≥70
n = 16
p = 0.02
f
Inherited mutations
n = 368
p = 0.03
SCN1A
0 5 10 15 20 25
Number of other hits
30 35
a
c
dCopy number variants Single nucleotide variants
n = 290
R = –0.25
p < 0.0001
De novo mutations
e
Fig. 4 Burden of other hits modulates quantitative phenotypes among probands with a first-hit copy-number variant (CNV) or single-
nucleotide variant (SNV) associated with neurodevelopmental disease. (a) Negative correlation between the number of other hits and full-scale IQ
(FSIQ) scores in individuals (n= 53) carrying 16 CNVs associated with neurodevelopmental disease (Pearson correlation, R= –0.36, p= 0.004). Probands
with 16p11.2 deletion (red), 16p11.2 duplication (green), 1q21.1 duplication (blue) and 7q11.23 duplication (yellow) are highlighted, while gray circles
represent probands with other rare CNVs. (b) Higher burden of other hits among probands with 16p11.2 deletion and FSIQ <70 (n= 17) compared with
probands with FSIQ ≥70 (n= 65, one-tailed Mann–Whitney, p= 0.08). (c) Negative correlation between the number of other hits and head circumference z-
scores (age ≥12 months, n= 80, Pearson correlation R= –0.26, p= 0.009) in probands with 16p11.2 deletion. (d) Autism probands with de novo disruptive
variants and available FSIQ scores (n= 290) show a moderate negative correlation (Spearman correlation coefficient, R= –0.25, p < 0.0001) between the
number of other hits and FSIQ scores. (e) Probands present an excess of other hits compared with their unaffected siblings (n= 184 pairs) carrying the same
inherited pathogenic variants (loss-of-function or damaging missense CADD ≥25) in genes recurrently disrupted in neurodevelopmental disease (Wilcoxon
signed-rank test, p= 0.03). (f) Enrichment of other hits among individuals with damaging variants in SCN1A (loss-of-function or missense CADD ≥25) and
intellectual disability (one-tailed Mann–Whitney, p= 0.02) compared with those without intellectual disability
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same genes is challenging. To understand the role of the
genetic background in the penetrance of inherited disruptive
variants in disease-associated genes, we analyzed 184 pairs of
autism probands and unaffected siblings who inherited the
same pathogenic variant in genes recurrently disrupted in
neurodevelopmental disorders (Table S12). We found a
greater enrichment of other hits in probands compared with
their unaffected siblings (Wilcoxon signed-rank test p= 0.03,
Fig. 4e), suggesting that rare variants likely contribute to
increased penetrance of neurodevelopmental phenotypes in
children with inherited pathogenic single-gene variants.
When we analyzed probands carrying pathogenic variants
in specific neurodevelopmental genes, we found that the
severity of cognitive deficits in individuals with damaging
variants in SCN1A was concordant with an excess of other
hits (probands with FSIQ <70, n= 8, median=16.5, versus
those with FSIQ ≥70, n= 8, median=8.5, one-tailed
Mann–Whitney, p= 0.02) (Fig. 4f). This observation could
also explain the diversity of other phenotypes co-occurring
with the disruption of the epilepsy-associated SCN1A gene,
such as motor delay and autism.31
Other hits involve disease-associated genes and affect core
cellular and developmental processes
To understand how other rare variants could modulate
phenotypes among probands with pathogenic first-hit var-
iants, we explored the functionality of genes with other hits
identified in all probands analyzed in our study. Overall, we
identified 3197 other hits encompassing a diverse set of 1615
functionally intolerant genes. Of these, 40.9% (660/1615) were
found to be extremely intolerant to loss-of-function variants
(probability of loss-of-function intolerance [pLI] metric ≥0.9).
These genes were also enriched for postsynaptic density genes,
genes encoding FMRP targets, chromatin-associated genes,
embryonically expressed genes, and essential genes compared
with the whole genome (52% vs. 26%, Chi-squared test,
p<0.0001).32,33 Interestingly, 44 of these genes with other hits
(such as CNTNAP2,MBD5, SCN1A, CHD8, and AUTS2) have
been recurrently associated with neurodevelopmental dis-
orders17 (Fig. S12), 58 genes have been previously identified as
a causative gene in simplex autism cases15,16 (Table S13), and
50 genes have been associated with skeletal, muscular,
cardiovascular, or renal disorders, as classified in the human
disease network (Table S14).34 We further assessed the
location of other-hit variants within a subset of genes
recurrently associated with disease, including RIMS1, DIP2A,
KDM5B, and ACOX2, and found no specificity for the
location of the other hits within the protein sequences
compared with previously reported de novo pathogenic
variants within these genes (Fig. 5a). In fact, in some cases,
we observed stopgain variants that were more premature in
the protein sequence than previously reported pathogenic
variants, suggesting that the other hit can potentially exert as
severe an effect as a primary variant, if these are true loss-of-
function variants. The allelic diversity of other likely
deleterious variants within these genes suggests that further
functional analysis should be performed to understand their
specific effects on modulating developmental phenotypes.
To further understand the functional role of genes carrying
rare variants, we performed Gene Ontology enrichment
analysis of genes with other hits in probands with de novo
pathogenic variants from the SSC and 16p11.2 deletion
probands from the SVIP cohort. We found that genes
carrying other hits in probands from both cohorts were
enriched for core processes, including cell signaling, cell
adhesion, and developmental processes (Fig. 5b, c, Tables S15,
S16). Although some of these genes have been individually
associated with a disease phenotype, further functional
analyses are required to understand potential interactions
between genes affected by both primary variants and other
hits, their cumulative burden, and ultimately their potential
contribution toward phenotypic variability.
DISCUSSION
In this study, we have explored the contribution of rare
variants in the genetic background toward the phenotypic
heterogeneity of disease-associated variants. Recently, exome
and genome sequencing studies have reported an increased
burden of rare deleterious variants toward risk for neurode-
velopmental disorders16,35,36 and combined parent-of-origin
inherited risk effects for autism.16,32,37 Our analysis supports a
complex model for neurodevelopmental disorders, and
further postulates how rare variants in the genetic background
modulate specific phenotypes in the presence of the same
disease-causing variant.2,11–14 We propose that a higher
burden of rare variants increases the likelihood of involving
a modifier gene within disease-related pathways, as well as
allows for a higher number of oligogenic combinations
potentially modulating the phenotype associated with the
first hit. Some primary variants more tolerant to changes in
the genetic background, such as the 16p12.1 deletion, are
transmitted through generations and only surpass the
threshold for severe disease with the accumulation of several
additional rare pathogenic variants. Other primary variants
that are often de novo, such as the 16p11.2 deletion, push the
genetic background closer to the threshold for severe
manifestation and therefore require a lesser contribution
from other hits. Similarly, highly penetrant syndromic CNVs
such as Smith–Magenis syndrome and Sotos syndrome, which
are mostly de novo and encompass genes more intolerant to
functional variation compared with variably expressive CNVs
(p=0.03, one-tailed Mann–Whitney, Table S17, Fig. S13),
would push the genetic liability beyond the threshold for
severe disease on their own.2,11 While additional variants may
not be necessary for complete penetrance of these disorders,
these variants can modify specific phenotype traits when
present. For example, deleterious variants in histone modifier
genes have been reported to contribute to heart defects in
22q11.2 deletion syndrome.38 This model would also apply for
single-gene disorders, where other hits potentially explain
discordant clinical features reported among affected carriers
of the same molecular alteration, as described for Rett
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syndrome and individuals with pathogenic variants in the
intellectual disability gene PACS1.39,40
Our observations that probands with a strong family history
exhibit severe clinical manifestation and a higher burden of
other hits also provide insights into the role of rare variants in
the genetic background toward the reported correlation
between parental profiles and clinical outcome in probands
carrying rare CNVs.28,29 Moreover, the observed higher
burden of other hits in the noncarrier parents in families
with strong family history suggests assortative mating, and
transmission of these hits to the proband potentially explains
the increased clinical severity. Similarly, in 16p11.2 deletion,
we observed that children who inherited the CNV presented
lower FSIQ scores (n=8, median FSIQ=75) than probands
with a de novo deletion (n=57, median FSIQ=85, one-tailed
Mann–Whitney, p=0.006, Fig. S14A), in agreement with
previous reports.6 This was also consistent with a nonsigni-
ficant excess of other hits among probands with an inherited
16p11.2 deletion (one-tailed Mann–Whitney, p=0.06,
Fig. S14B) compared with probands with a de novo deletion.
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Fig. 5 Rare variants in the genetic background affect core biological processes and disease-associated genes. (a) Examples of nonspecificity in the
location of other hits in protein domains compared with first-hits. Location of variants in the protein sequences of RIMS1, DIP2A, KDM5B and ACOX2, genes
with other hits (green arrows) and previously reported de novo disruptive variants in simplex autism cases (red arrows). Genes with other hits found in
(b) autism spectrum disorder (ASD) probands carrying de novo disruptive variants (Simons Simplex Cohort; SSC) and (c) probands with the 16p11.2 deletion
(Simons Variation in Individuals Project; SVIP) are enriched in core biological processes (FDR <0.05 with Bonferroni correction). Clusters of enriched Gene
Ontology (GO) terms for “developmental processes,” “cell signaling,” “cell adhesion,” and “transport” functions are present among other hits found in
each cohort. The size of each circle represents the number of genes annotated for each GO term; red shading of each circle represents the FDR for
enrichment of each GO term among genes with other hits, with darker shades indicating a lower FDR. Line thickness represents the number of shared genes
between pairs of GO terms. FDR values of the enriched GO terms are detailed in Tables S15-S16. FDR False discovery rate
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These results highlight the importance of eliciting family
history of psychiatric and neurodevelopmental disease for
more accurate diagnostic assessment of the affected children.
Overall, our results suggest a multidimensional effect of rare
variants in the genetic background toward clinical features,
and their contribution to specific phenotypic domains
depends on the extent to which the primary variant sensitizes
an individual toward a specific phenotypic trajectory. An
important observation from our study is that a large number
of disease-associated variants deemed to be solely causative
for the disorder are in fact accompanied by a substantial
amount of rare genetic variation. Longitudinal and quantita-
tive phenotyping across multiple developmental domains in
all family members, along with genome sequencing studies in
affected and seemingly asymptomatic individuals with a
primary variant, are necessary for a more accurate under-
standing of these complex disorders. Therefore, it is critical
that even after identifying a likely diagnostic pathogenic
variant, further analysis of the genetic background must be
performed to provide appropriate counseling and
management.
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